Huckell V F, Bernstein V, Cairns J A, Crowell R, Dagenais G R, Higginson L A, Isserow S, Laramée P, Liu P, McCans J L, Orchard R C, Prewitt R, Quinn B P, Samson M, Turazza F, Warnica J W, Wielgosz A
Vancouver Hospital, British Columbia.
Can J Cardiol. 1997 Feb;13(2):161-9.
There is an increasing body of clinical trial evidence to support the use of angiotensin-converting enzyme (ACE) inhibitors in the management of patients following myocardial infarction (MI). Enthusiasm for the use of ACE inhibitors in the acute phase of MI had previously been tempered by the adverse results of an early trial. However, exciting new information is available from several large, randomized studies that has not only quelled those initial concerns but also attests to the efficacy of using this class of medication in the first 24 h after an acute MI. A Canadian National Opinion Leader Symposium was held in November 1995 to review the results of the major ACE inhibitor clinical trials and to discuss key issues and controversies surrounding their use in acute MI. The focus of this paper, the first of two parts, is on the results of the major ACE inhibitor clinical trials.
越来越多的临床试验证据支持在心肌梗死（MI）患者的管理中使用血管紧张素转换酶（ACE）抑制剂。此前，一项早期试验的不良结果曾抑制了人们在MI急性期使用ACE抑制剂的热情。然而，几项大型随机研究提供了令人振奋的新信息，这些信息不仅消除了最初的担忧，还证明了在急性MI后24小时内使用这类药物的有效性。1995年11月召开了一次加拿大全国意见领袖研讨会，以审查主要ACE抑制剂临床试验的结果，并讨论围绕其在急性MI中使用的关键问题和争议。本文作为两部分中的第一部分，重点关注主要ACE抑制剂临床试验的结果。
